Suppr超能文献

恶性胸腺瘤的自然史与治疗

Natural history and treatment of malignant thymoma.

作者信息

Cowen D, Hannoun-Levi J M, Resbeut M, Alzieu C

机构信息

Department of Radiotherapy, Institut Paoli-Calmettes, Marseille, France.

出版信息

Oncology (Williston Park). 1998 Jul;12(7):1001-5; discussion 1006.

PMID:9684271
Abstract

Thymomas are rare, slow-growing neoplasms that are considered to be malignant because of their potential invasiveness. The most widely used staging system is that of Masaoka and colleagues, which takes into account the extent of clinical and histopathologically determined disease involvement. However, recent data suggest that the staging system of the French Study Group on Thymic Tumors (GETT system), which is based on the surgical and pathologic features of the tumor, may be superior to the Masaoka system. Total resection followed by radiation therapy is the treatment of choice for all thymomas, except stage IA tumors, which can be treated with surgery alone. Chemotherapy can improve the outcome of invasive Masaoka stage III and IV thymomas or recurrent thymomas. Only platinum-containing regimens show consistent efficacy.

摘要

胸腺瘤是罕见的、生长缓慢的肿瘤,因其潜在的侵袭性而被视为恶性肿瘤。应用最广泛的分期系统是马萨oka及其同事提出的分期系统,该系统考虑了临床和组织病理学确定的疾病累及范围。然而,最近的数据表明,基于肿瘤手术和病理特征的法国胸腺肿瘤研究组分期系统(GETT系统)可能优于马萨oka系统。除IA期肿瘤可仅行手术治疗外,所有胸腺瘤的首选治疗方法是手术全切后进行放射治疗。化疗可改善侵袭性马萨oka III期和IV期胸腺瘤或复发性胸腺瘤的治疗效果。只有含铂方案显示出持续疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验